Lilly is paying billions for Orna’s circular RNA, which could allow the patient’s own body to generate cell therapies. https://t.co/f7hPZetWSr ...

Core Viewpoint - Novo Nordisk has initiated a U.S. patent lawsuit against Hims & Hers, targeting the sale of compounded versions of its weight-loss drug Wegovy, marking a significant escalation in its legal strategy against compounding pharmacies [1][2]. Legal Context - This lawsuit is Novo's first against a compounding pharmacy in the U.S. regarding Wegovy, coinciding with the FDA's announcement that the active ingredient semaglutide is no longer in short supply, which has lessened concerns about public backlash from patent enforcement [2][3]. - Hims & Hers recently launched a $49 compounded version of Wegovy but quickly retreated after the FDA indicated it would take action against the company [3]. Financial Implications - Hims & Hers has projected its total revenue to exceed $2.3 billion by 2025 and aims for $6.5 billion by 2030, indicating rapid growth in the telehealth sector [4]. Regulatory Environment - U.S. regulations permit compounding pharmacies to produce and sell brand-name medicines if they are in short supply, but without a shortage, compounding is generally allowed only for customized patient needs [5]. - The FDA had previously listed semaglutide as in short supply in 2022, which facilitated the rise of compounding, but declared the shortage over in February 2025 [6]. Previous Legal Actions - Novo Nordisk has previously filed lawsuits against smaller compounding pharmacies for selling unsafe or falsely advertised Wegovy "knockoffs," focusing on safety and trademark rights during the semaglutide shortage [7].

Core Viewpoint - Novo Nordisk has initiated a U.S. patent lawsuit against Hims & Hers, indicating a strategic move to protect its intellectual property against companies offering compounded versions of its products [1] Company Summary - The lawsuit represents a significant step in Novo Nordisk's ongoing efforts to combat the sale of compounded drugs that may infringe on its patents [1] - This legal action highlights the competitive landscape in the pharmaceutical industry, particularly concerning patent rights and the protection of proprietary formulations [1] Industry Summary - The case underscores the increasing tensions between traditional pharmaceutical companies and newer entrants in the market that provide alternative drug formulations [1] - The outcome of this lawsuit could have broader implications for the industry, potentially influencing how compounded drugs are regulated and marketed in the future [1]

Core Viewpoint - China Resources Pharmaceutical (华润医药) announced that its non-wholly owned subsidiary, Dong'e Ejiao (东阿阿胶), has decided to invest in and construct a health consumer goods industrial park, which will enhance its production capabilities and support the growth of its health consumer goods business [1][2]. Group 1: Investment and Construction Details - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing, logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1]. - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, which will include production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1]. - The total investment for the project is estimated to be around RMB 1.485 billion, with fixed asset investment amounting to approximately RMB 1.421 billion and working capital of about RMB 64 million [1]. Group 2: Strategic Importance - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine [2]. - The project is designed to establish a dual-driven business growth model combining pharmaceuticals and health consumer goods, fostering a second growth curve while addressing the urgent needs for the development of health consumer goods [2]. - The existing industrial park faces limitations in expansion and capacity bottlenecks, which hinder the ability to meet the rapid upgrades and iterations in health consumer goods, making the new construction essential for maintaining competitive advantages [2].

Core Insights - Eli Lilly has achieved significant success in the GLP-1 drug market, with a stock price increase of 200% over the past three years and a leadership position in the U.S. market, holding over 60% market share [1][6][10] - The obesity drug market is projected to reach nearly $100 billion by the end of the decade, indicating potential for continued growth for Eli Lilly [7] Company Performance - Eli Lilly's revenue has shown double-digit growth, with Mounjaro and Zepbound generating over $11 billion in revenue during the recent quarter, both experiencing triple-digit revenue gains [1][6] - The company's gross margin stands at 85.40%, and it has a market capitalization of $988 billion [9] Product Overview - GLP-1 drugs, including Eli Lilly's tirzepatide (Mounjaro and Zepbound), help manage blood sugar levels and appetite, contributing to their popularity [4][5] - Eli Lilly is also developing orforglipron, an oral weight loss candidate currently under regulatory review, which could further enhance its market position [5][9] Competitive Landscape - While Novo Nordisk was the first to market with GLP-1 drugs, Eli Lilly has been gaining market share and has outperformed competitors in clinical trials [6][9] - Other companies, such as Pfizer and Viking Therapeutics, are looking to enter the market, but Eli Lilly's established brand strength and product efficacy are expected to sustain its revenue growth [10]

Drugmaker Lupin has entered into a Settlement and License Agreement with Astellas Pharma Inc, involving a patent infringement dispute over its product ‘Mirabegron’.“Lupin will pay Astellas $90 million, which includes a Prepaid Option Payment of $75 million, and a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027,” the company told the stock exchanges.The product is indicated for treating an overactive bladder with symptoms of urge urinary ...

近日，丽珠集团发布投资者调研记录，围绕公司在免疫领域的创新药莱康奇塔单抗及疫苗领域的研发进展进行了详细 交流。 在疫苗领域，公司正在推进流感灭活疫苗和重组人促卵泡激素注射液的研发。四价重组蛋白流感疫苗预计在2026年上 半年进入II期临床，而重组人促卵泡激素注射液预计在2026年内获批上市。公司强调将继续利用AI技术提升研发效 率，缩短研发周期，进一步增强市场竞争力。 公告中提到，在免疫领域，莱康奇塔单抗作为公司的核心标志性成果，目前正在进行中重度银屑病及强直性脊柱炎的 临床研究。其中银屑病适应症已申报上市并纳入CDE优先审评，预计最快在今年底获批。强直性脊柱炎适应症预计在 2026年二季度申报上市。III期临床研究显示，莱康奇塔单抗组第12周PASI100应答率为49.5%，显著优于司库奇尤单抗 的40.2%。此外，公司还启动了海外合作洽谈，未来将探讨新适应症开发。 （丽珠集团公告） ...

白云山公告称，其分公司何济公制药厂收到国家药监局签发的口洁喷雾剂《药品补充申请批准通知 书》，批准变更药品规格，将其由"每瓶装20ml"规范为"每1ml相当于饮片240mg，含薄荷脑13mg、桉油 2.5μl"。何济公制药厂于2025年11月4日递交申请，11月17日获受理。截至公告日，该药品研发已投入约 241.36万元。2024年国内市场销售额5064万元，何济公制药厂销售收入1894万元。此次获批对当期业绩 无重大影响。 ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton as a Potential First-in-Class Therapy for Narcolepsy Type 1. ...

Core Insights - The company anticipates revenue growth for 2026 to be in the mid-to-high single-digit percentage range, indicating a positive outlook for future sales performance [1] - Core earnings per share are expected to increase by a low double-digit percentage, reflecting strong profitability expectations [1]